In the pursuit of market outperformance, investors navigate the landscape of stock selection. The right picks can play a pivotal role in enhancing your wealth.
The closing price of Kura Oncology Inc (NASDAQ: KURA) was $6.47 for the day, up 0.47% from the previous closing price of $6.44. In other words, the price has increased by $0.47 from its previous closing price. On the day, 1.08 million shares were traded. KURA stock price reached its highest trading level at $6.555 during the session, while it also had its lowest trading level at $6.405.
Ratios:
Our analysis of KURA’s different ratios will help us gain a deeper understanding of the company. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 0.85 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 5.07. For the most recent quarter (mrq), Quick Ratio is recorded 8.07 and its Current Ratio is at 8.07. In the meantime, Its Debt-to-Equity ratio is 0.05 whereas as Long-Term Debt/Eq ratio is at 0.04.
On October 24, 2024, UBS started tracking the stock assigning a Buy rating and target price of $27.
Stifel Downgraded its Buy to Hold on October 14, 2024, whereas the target price for the stock was revised from $26 to $19.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on May 19 ’25 when Bair Teresa Brophy sold 1,559 shares for $5.96 per share. The transaction valued at 9,292 led to the insider holds 107,948 shares of the business.
FORD KATHLEEN sold 1,558 shares of KURA for $9,777 on May 19 ’25. The Chief Operating Officer now owns 21,367 shares after completing the transaction at $6.28 per share. On May 19 ’25, another insider, FORD KATHLEEN, who serves as the Officer of the company, bought 1,558 shares for $5.96 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, KURA now has a Market Capitalization of 560138304 and an Enterprise Value of -78698776. For the stock, the TTM Price-to-Sale (P/S) ratio is 8.24 while its Price-to-Book (P/B) ratio in mrq is 1.43. Its current Enterprise Value per Revenue stands at -1.157 whereas that against EBITDA is 0.388.
Stock Price History:
The Beta on a monthly basis for KURA is 0.41, which has changed by -0.69321954 over the last 52 weeks, in comparison to a change of 0.16564083 over the same period for the S&P500. Over the past 52 weeks, KURA has reached a high of $21.60, while it has fallen to a 52-week low of $5.41. The 50-Day Moving Average of the stock is 5.12%, while the 200-Day Moving Average is calculated to be -28.82%.
Shares Statistics:
KURA traded an average of 1.28M shares per day over the past three months and 1337860 shares per day over the past ten days. A total of 86.57M shares are outstanding, with a floating share count of 82.28M. Insiders hold about 4.96% of the company’s shares, while institutions hold 89.95% stake in the company. Shares short for KURA as of 1751241600 were 7859540 with a Short Ratio of 6.13, compared to 1748563200 on 8357660. Therefore, it implies a Short% of Shares Outstanding of 7859540 and a Short% of Float of 9.1000006.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
Earnings Estimates
At present, 10.0 analysts are actively evaluating the performance of Kura Oncology Inc (KURA) in the stock market.The consensus estimate for the next quarter is -$0.64, with high estimates of $0.15 and low estimates of -$0.89.
Analysts are recommending an EPS of between -$0.14 and -$3.3 for the fiscal current year, implying an average EPS of -$2.06. EPS for the following year is -$1.95, with 10.0 analysts recommending between $0.88 and -$4.82.
Revenue Estimates
A total of 13 analysts have provided revenue estimates for KURA’s current fiscal year. The highest revenue estimate was $438.6M, while the lowest revenue estimate was $19.31M, resulting in an average revenue estimate of $161.42M. In the same quarter a year ago, actual revenue was $53.88MBased on 14 analysts’ estimates, the company’s revenue will be $204M in the next fiscal year. The high estimate is $451.2M and the low estimate is $20.05M.
